Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
Status:
Not yet recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Approximately 80 patients affected by moderate to severe psoriasis will be screened for the
presence of LL37( and ADAMTSL5 autoreactive T-cells in their blood at Day 0. Patients whose
lymphocytes reacted with proliferation to LL37 or ADAMTSL5 will receive SKYRIZI (Risakizumab)
at Day 1, week 4, 16, 28, 40. LL37 and ADAMTSL5-specific T-cell responses will be evaluated
at Day 0, week 16, week 28 and week 52. Each patient will be followed for 52 weeks.